Aneurysmal Subarachnoid Hemorrhage (aSAH) Market

Jan 05, 2021

30 likes | 111 Vues

Aneurysmal SAH is an abrupt onset of a severe headache and/or loss of consciousness, with or without focal neurological signs, with CT, necropsy, or lumbar puncture, evidence of focal or generalized blood in the subarachnoid space. As per the Delveinsight, the market size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in 7MM was USD 155.47 Million in 2017. The total incident cases of Aneurysmal Subarachnoid Hemorrhage (aSAH) in 7MM was 53,611 in 2017. It is observed that the incident population share of aSAH in the United States was 24.5% of the total 7MM share. New potential targets for therapeutics development and strengthening of the molecular basis of SAH are the key drivers for Aneurysmal Subarachnoid Hemorrhage (aSAH) Market. Some of the key companies in the Aneurysmal Subarachnoid Hemorrhage (aSAH) Market include Evgen Pharma, Idorsia Pharmaceuticals, Grace Therapeutics, Edge Therapeutics, PDS Biotechnology Corporation, BIT Pharma and many others. Source: Aneurysmal Subarachnoid Hemorrhage (aSAH) Market

DelveInsight

Télécharger la présentation

Aneurysmal Subarachnoid Hemorrhage (aSAH) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D